High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease
Authors Kapur NK, Ashen D, Blumenthal RS
Published 8 February 2008 Volume 2008:4(1) Pages 39—57
Navin K Kapur, Dominique Ashen, Roger S Blumenthal
Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Abstract: Since the pioneering work of John Gofman in the 1950s, our understanding of high density lipoprotein cholesterol (HDL-C) and its relationship to coronary heart disease (CHD) has grown substantially. Numerous clinical trials since the Framingham Study in 1977 have demonstrated an inverse relationship between HDL-C and one’s risk of developing CHD. Over the past two decades, preclinical research has gained further insight into the nature of HDL-C metabolism, specifically regarding the ability of HDL-C to promote reverse cholesterol transport (RCT). Recent attempts to harness HDL’s ability to enhance RCT have revealed the complexity of HDL-C metabolism. This review provides a detailed update on HDL-C as an evolving therapeutic target in the management of cardiovascular disease.
Keywords: high density lipoprotein cholesterol (HDL-C), coronary, atherosclerosis, reverse cholesterol transport
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]